Wholesale Medicine 40mg Pantoprazole Capsule Powder CAS 102625-70-7

• Certification: GMP
• Age Group: Adults
• Type: Capsule
• Gender: Unisex
• Feature: Internal Medicine
• Packaging: Box
• Model NO.: 40mg
• Storage Note: Moisture Proof
• Logo Printing: With Logo Printing
• Product Type: Food
• State: Solid
• Purity: >99%
• Type a: Pharmaceutical Intermediates
• Transport Package: Box Packing
• Specification: 2mg, 5mg, 10mg
• Trademark: OEM service
• Origin: China
• HS Code: 3004909099
• Production Capacity: 5000box Per Week

Product Description

Pantoprazole enteric capsule

Pantoprazole, an irreversible proton pump inhibitor, reached its first market worldwide in Germany for acute treatment of gastric and duodenal ulcers and gastroesophageal reflux disease. Proton pump inhibitors are more effective than other strategies in inhibiting acid secretion since they function at the final step of acid production, therefore, provide superior symptom relief and healing in all acid related diseases.

As the third substituted benzimidazole proton pump inhibitor marketed, pantoprazole not only has superior ulcer-preventing effect but also is more potent than omeprazole in healing acetic acid-induced gastric and duodenal ulcers with extremely low acute toxicity. The mechanism of action for this class of compounds has been suggested to be mediated via the protonated form of the molecule which selectively reacts with cysteines present on the extracytoplasmic face of the enzyme to form covalent disulfide bonds.

Specification	40mg  2x10/box
Shelf life	3Years
Storage	Store in a cool and dry place below 25ºC, protect from light

Synonyms:    5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-yridinyl)methyl]sulfinyl]-1h-benzimidazole;5-(DIFLUOROMETHOXY)-2-[[(3,4-DIMETHOXY-2-PYRIDINYL)METHYL]SULFINYL]-1H-BENZIMIDAZOLE;6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1h-benzimidazole;PANTOPRAZOLE;PANTOPRAZOLE SODIUM 98-102%;Pantoprazole (base and/or unspecified salts);Pantoprazole&Int.;5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-3H-benzoimidazole



Therapeutic indications

- Reflux oesophagitis.

- Gastric and duodenal ulcer.

- Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions.



Dose and method of administration

not recommended for use in patients below 18 years of age.

Intravenous administration of Pantoprazole 40 mg Powder for Solution for Injection is recommended only if oral administration is not appropriate. Data are available on intravenous use for up to 7 days. Therefore, as soon as oral therapy is possible, treatment with Pantoprazole 40 mg Powder for Solution for Injection IV should be discontinued and 40 mg pantoprazole p.o. should be administered instead.

The recommended intravenous dose is one vial of Pantoprazole 40 mg Powder for Solution for Injection (40 mg pantoprazole) per day.

For the long-term management of Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions patients should start their treatment with a daily dose of 80 mg Pantoprazole 40 mg Powder for Solution for Injection. Thereafter, the dose can be titrated up or down as needed using measurements of gastric acid secretion to guide. With doses above 80 mg daily, the dose should be divided and given twice daily. A temporary increase of the dose above 160 mg pantoprazole is possible but should not be applied longer than required for adequate acid control.

In case a rapid acid control is required, a starting dose of 2 x 80 mg Pantoprazole 40 mg Powder for Solution for Injection is sufficient to manage a decrease of acid output into the target range (< 10 mEq/h) within one hour in the majority of patients.